Celldex Therapeutics Inc

This management proposal asks shareholders to authorize an amendment to the Company’s 2021 Omnibus Equity Incentive Plan to increase the aggregate share reserve by 3.4 million shares (from 9.5 million to 12.9 million, plus unused roll‑ins from the prior plan) and to explicitly expand and clarify the Plan’s tax‑withholding mechanics. Management and the Board state the increase is driven by anticipated hiring and commercialization preparations that will require additional equity awards to attract and retain executive, scientific and commercial talent; the Company cites its pipeline progress and potential commercialization activities as context for these grants. The amendment also codifies alternative withholding methods — cash payment, withholding from cash payouts, withholding shares otherwise issuable, participant delivery of already‑owned shares, or facilitating a sale of shares issued on settlement — and caps share withholding to amounts necessary to satisfy statutory tax rates or to avoid adverse accounting treatment. By clarifying permissible withholding mechanisms (including net share issuance and sale facilitation), the amendment seeks to reduce execution risk and accounting uncertainty associated with satisfying tax obligations tied to equity awards. The Board recommends for approval, emphasizing alignment of employee and shareholder interests via equity and the need for a sufficient equity pool as the company scales toward commercialization. Key governance safeguards remain: awards are subject to Committee discretion, annual limits for non‑employee director awards, and anti‑repricing provisions without stockholder approval. If approved, the amendment will increase available awards and expand administrative flexibility; if not approved, the Company would continue under the current Plan terms and may need to rely on alternate, potentially more costly or less efficient retention tools. Vote implications: a FOR vote supports management’s efforts to fund compensation and retention through equity and to standardize tax‑withholding practice; an AGAINST vote limits the Company’s ability to grant further equity under the 2021 Plan and may increase pressure on cash compensation or require a future, potentially more dilutive proposal.

This advisory management proposal requests a nonbinding affirmation from shareholders of the Company’s executive compensation program as disclosed in the proxy statement (CD&A, compensation tables and narrative). Management frames its compensation philosophy around pay‑for‑performance, combining base salary, annual cash incentive bonuses tied to corporate goals and multi‑year equity (stock option) awards to align executives’ interests with long‑term shareholder value, and notes independent consultant benchmarking and Committee oversight. The filing highlights that 2025 corporate goals were met (100% payout factor) and details significant programmatic milestones—especially progress with barzolvolimab and the bispecific platform—that the Compensation Committee cites as justifying payouts and equity grants in 2025. The advisory nature means the vote will not be binding, but the Board and Compensation Committee intend to consider the result when setting future compensation; the filing points to a historically strong prior say‑on‑pay result (~99% support) as evidence of alignment with shareholders. From a governance perspective, the Committee retains discretion, uses peer groups and an independent consultant, has clawback and stock‑ownership policies, and structures long‑term awards with multi‑year vesting to mitigate short‑term risk‑taking. A FOR vote signals shareholder support for the current program and its implementation during a development/commercial transition; an AGAINST vote would prompt the Committee to engage with shareholders and potentially revise program elements to address concerns. For investors evaluating the proposal, key considerations include the Company’s stage (late‑stage clinical and commercialization planning), the degree of CEO and NEO pay linked to measurable corporate milestones, the total dilution from equity grants (including the related Proposal 3 increase), and prior high shareholder approval which suggests prior alignment but does not preclude future scrutiny.